Literature DB >> 31309762

[Effects of aerobic glycolysis on pathogenesis and drug resistance of non-Hodgkin lymphoma].

Li Xu1, Ming Xu2, Xiangmin Tong3.   

Abstract

It has been shown that aerobic glycolysis (AG) plays an important role in the pathogenesis and resistance mechanism of non-Hodgkin lymphoma (NHL) in recent years. Signaling pathway related to abnormal activation of AG can increase the level of AG in lymphatic and hematopoietic cells, while the enzymes related to the activity of AG are involved in the pathogenesis and prognosis of NHL. Drugs that inhibit AG can also inhibit NHL cells in vitro. Drugs inhibiting AG may increase the sensitivity of chemotherapeutic agents and prevent drug resistance. In this article, the role of signaling pathway proteins and regulatory genes related to AG in the pathogenesis and drug resistance of NHL are reviewed, and the AG as a target in the clinical diagnosis and treatment of NHL is discussed.

Entities:  

Mesh：

Year:  2019        PMID： 31309762      PMCID： PMC8800782          DOI： 10.3785/j.issn.1008-9292.2019.04.15

Source DB:  PubMed          Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban        ISSN： 1008-9292


  25 in total

Review 1.  Sugar-free approaches to cancer cell killing.

Authors:  N El Mjiyad; A Caro-Maldonado; S Ramírez-Peinado; C Muñoz-Pinedo
Journal:  Oncogene       Date:  2010-10-25       Impact factor: 9.867

2.  The indoleamine 2,3-dioxygenase inhibitor 1-methyl-tryptophan suppresses mitochondrial function, induces aerobic glycolysis and decreases interleukin-10 production in human lymphocytes.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Aggeliki Karioti; Georgia Antoniadi; Vassilios Liakopoulos; Konstantina Dafopoulou; Spyros Pournaras; Georgios Koukoulis; Ioannis Stefanidis
Journal:  Immunol Invest       Date:  2012-05-17       Impact factor: 3.657

3.  Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC).

Authors:  Federico Fallanca; Pierpaolo Alongi; Elena Incerti; Luigi Gianolli; Maria Picchio; Irfan Kayani; Jamshed Bomanji
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-05-07       Impact factor: 9.236

4.  Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma.

Authors:  Aadra P Bhatt; Sarah R Jacobs; Alex J Freemerman; Liza Makowski; Jeffrey C Rathmell; Dirk P Dittmer; Blossom Damania
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-29       Impact factor: 11.205

5.  A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors.

Authors:  Luis E Raez; Kyriakos Papadopoulos; Alejandro D Ricart; E Gabriella Chiorean; Robert S Dipaola; Mark N Stein; Caio M Rocha Lima; James J Schlesselman; Khaled Tolba; Virginia K Langmuir; Stewart Kroll; Donald T Jung; Metin Kurtoglu; Joseph Rosenblatt; Theodore J Lampidis
Journal:  Cancer Chemother Pharmacol       Date:  2012-12-11       Impact factor: 3.333

6.  The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma.

Authors:  Stephanos Pavlides; Diana Whitaker-Menezes; Remedios Castello-Cros; Neal Flomenberg; Agnieszka K Witkiewicz; Philippe G Frank; Mathew C Casimiro; Chenguang Wang; Paolo Fortina; Sankar Addya; Richard G Pestell; Ubaldo E Martinez-Outschoorn; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2009-12-05       Impact factor: 4.534

7.  P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.

Authors:  Sunil Iyengar; Andrew Clear; Csaba Bödör; Lenushka Maharaj; Abigail Lee; Maria Calaminici; Janet Matthews; Sameena Iqbal; Rebecca Auer; John Gribben; Simon Joel
Journal:  Blood       Date:  2013-01-22       Impact factor: 22.113

8.  Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.

Authors:  Zi-Zhen Xu; Zu-Guang Xia; Ai-Hua Wang; Wen-Fang Wang; Zhi-Yin Liu; Li-Yun Chen; Jun-Min Li
Journal:  Ann Hematol       Date:  2013-05-02       Impact factor: 3.673

9.  Effects of orexin A on glucose metabolism in human hepatocellular carcinoma in vitro via PI3K/Akt/mTOR-dependent and -independent mechanism.

Authors:  Yuanyuan Liu; Yuyan Zhao; Lei Guo
Journal:  Mol Cell Endocrinol       Date:  2015-11-06       Impact factor: 4.102

10.  Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma.

Authors:  Richard A Noble; Natalie Bell; Helen Blair; Arti Sikka; Huw Thomas; Nicole Phillips; Sirintra Nakjang; Satomi Miwa; Rachel Crossland; Vikki Rand; Despina Televantou; Anna Long; Hector C Keun; Chris M Bacon; Simon Bomken; Susan E Critchlow; Stephen R Wedge
Journal:  Haematologica       Date:  2017-04-06       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.